

1 Prediction of Multiple Individual Primary Cardiovascular Events Using Pooled 2 Cohorts

3
4 Abbreviated Title: Multiple Events Prediction

5
6 Keywords: Pooled cohort equation, blood pressure, cholesterol, myocardial infarction,
7 stroke, kidney disease

8
9 Authors:

10 Jeremy B. Sussman, MD, MS^{1,2,3}; Rachael T. Whitney, PhD¹; James F. Burke, MD,
11 MS⁴; Rodney A. Hayward, MD, MS^{1,2,3}; Andrzej Galecki, MD, PhD^{1,5}; Stephen Sidney,
12 MD, MPH⁶; Norrina Bai Allen, PhD⁷; Rebecca F. Gottesman, MD, PhD⁸; Susan R.
13 Heckbert, MD, PhD⁹; William T. Longstreth, MD^{9,10}; Bruce M Psaty, MD, PhD^{9,11,12};
14 Mitchell S.V. Elkind, MD, MS¹³; Deborah A. Levine, MD, MPH^{1,3}

15
16 1: Department of Internal Medicine, University of Michigan, Ann Arbor, MI
17 2: Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI
18 3: Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI
19 4: Department of Neurology, The Ohio State University, Columbus, OH
20 5: Department of Biostatistics, University of Michigan, Ann Arbor, MI
21 6: Kaiser Permanente Northern California Division of Research, Oakland, CA
22 7: Department of Internal Medicine, Northwestern University, Chicago, IL
23 8: Department of Neurology, Johns Hopkins University, Baltimore, MD
24 9: Department of Epidemiology, University of Washington, Seattle, WA
25 10: Department of Neurology, University of Washington, Seattle, WA
26 11: Cardiovascular Health Research Unit, Department of Medicine, University of
27 Washington, Seattle, WA
28 12: Department of Health Systems and Population Health, University of Washington,
29 Seattle, WA
30 13: Department of Neurology, Vagelos College of Physicians and Surgeons, and
31 Department of Epidemiology, Mailman School of Public Health, Columbia University,
32 New York City, NY

33
34 Title Character count: 86

35 Abstract word count: 343

36 Word count paper: 3215

37 Number of references: 25

38 Number of Tables: 4

39 Number of Figures: 1 (plus 8 supplemental figures and 8 supplemental tables)

40
41 Corresponding Author:

42 Jeremy B Sussman, MD MS

43 2800 Plymouth Road

44 Building 16, Room 335e

45 Ann Arbor MI 48109-2800

46 415-939-7121

47 jeremysu@med.umich.edu

48

49 **Abstract**

50

51 **Introduction**

52

53 Most current clinical risk prediction scores for cardiovascular disease prevention use a
54 composite outcome. Risk prediction scores for specific cardiovascular events could
55 identify people who are at higher risk for some events than others informing
56 personalized care and trial recruitment. We sought to predict risk for multiple different
57 events, describe how those risks differ, and examine if these differences could improve
58 treatment priorities.

59

60 **Methods**

61

62 We used participant-level data from five cohort studies. We included participants
63 between 40 and 79 years old who had no history of myocardial infarction (MI), stroke, or
64 heart failure (HF). We made separate models to predict 10-year rates of first
65 atherosclerotic cardiovascular disease (ASCVD), first fatal or nonfatal MI, first fatal or
66 nonfatal stroke, new-onset HF, fatal ASCVD, fatal MI, fatal stroke, and all-cause
67 mortality using established ASCVD risk factors. To limit overfitting, we used elastic net
68 regularization with $\alpha = 0.75$. We assessed the models for calibration, discrimination,
69 and for correlations between predicted risks for different events. We also estimated the
70 potential impact of varying treatment based on patients who are high risk for some
71 ASCVD events, but not others.

72

73 **Results**

74

75 Our study included 24,505 people; 55.6% were women, and 20.7% were non-Hispanic
76 Black. Our models had C-statistics between 0.75 for MI and 0.85 for HF, good
77 calibration, and minimal overfitting. The models were least similar for fatal stroke and all
78 MI (0.58). In 1,840 participants whose risk of MI but not stroke or all-cause mortality was
79 in the top quartile, we estimate one blood pressure-lowering medication would have a
80 2.4% chance of preventing any ASCVD event per 10 years. A moderate-strength statin
81 would have a 2.1% chance. In 1,039 participants who had top quartile risk of stroke but
82 not MI or mortality, a blood pressure-lowering medication would have a 2.5% chance of
83 preventing an event, but a moderate-strength statin, 1.6%.

84

85 **Conclusion**

86

87 We developed risk scores for eight key clinical events and found that cardiovascular risk
88 varies somewhat for different clinical events. Future work could determine if tailoring
89 decisions by risk of separate events can improve care.

90

91

92 **Background**

93
94 Risk prediction is a the key element of all treatment recommendations in cardiovascular
95 primary prevention.¹⁻⁵ In particular, the risk score developed from the Pooled Cohort
96 Equations (PCEs) is at the center of primary prevention recommendations for
97 cholesterol reduction, blood pressure (BP) treatment, and aspirin use.^{2,6} The PCEs
98 were a substantial advance. By combining multiple populations, all with well-validated
99 data, they were based on a wealth of evidence that previous cardiovascular risk scores
100 lacked.

101
102 One key limitation of the PCEs is that they only predict a single composite outcome –
103 primary major atherosclerotic cardiovascular disease (ASCVD) events, defined as
104 myocardial infarction (MI) or stroke among participants who have never had one before.
105 Developing scores to predict distinct multiple separate cardiovascular outcomes, such
106 as MI, stroke, heart failure (HF), ASCVD mortality, and total mortality, could be useful,
107 especially since treatments are not uniformly effective across these events. For
108 example, since BP reduction has a larger effect on stroke than on MI and low-density
109 lipoprotein (LDL) cholesterol lowering has a larger effect on MI than stroke,^{7,8} identifying
110 patients at especially high risk for specific event types might improve treatment
111 decisions. In fact, accounting for these types of differences could improve health
112 through multiple mechanisms, most obviously, by enabling more effective tailoring of
113 treatment approaches to individual people. Predicting specific outcome types could also
114 help since many people struggle to understand composite risk scores and may have
115 greater fear for some event types, such as a strong desire to never have a stroke.
116 Finally, these scores could also be used in decision analysis and cost-effectiveness
117 analyses whenever a new treatment is more effective at preventing one type of ASCVD
118 event than another.

119
120 In this study we used individual participant data from five well-characterized US
121 cardiovascular cohorts to create risk scores for multiple clinical event types. We also
122 assessed the risk scores for reliability and accuracy, examined correlations between
123 risk for the different event types, and examined the differences in participants at risk for
124 the different event types. Specifically, we sought to assess if we could predict first
125 ASCVD, first MI, first stroke, new onset HF, fatal ASCVD, fatal MI, fatal stroke, and all-
126 cause mortality; if we could identify participants who have meaningfully different risk for
127 one type of event than others; and if we could estimate how these distinctions might
128 alter treatment priorities.

129 **Methods**

130
131
132 **General:** This is a study from the larger BP COG study, which was designed to
133 understand the relationships between BP levels and cognitive decline in Black, White,
134 and Hispanic participants. BP COG analyzed pooled individual participant data from
135 large, high-quality NIH-funded cohort studies, some of which overlap with those in the
136 PCEs, specifically Atherosclerosis Risk in Communities Study (ARIC), Cardiovascular
137 Health Study (CHS), and Framingham Offspring Study (FOS). Our dataset also includes

138 the Northern Manhattan Study (NOMAS) and Multi-Ethnic Study of Atherosclerosis
139 (MESA), which provide two populations of Latino participants. It does not include the
140 original Framingham study, which was conducted in a period when ASCVD rates and
141 case ascertainment were different from today, or Coronary Artery Risk Development in
142 Young Adults, for which the baseline participant age was below our studies' age
143 eligibility. Data were collected from January 1971 to December 2019.

144
145 **Population:** Participants ≥ 40 and <80 years of age at baseline, who were Black, White,
146 or Hispanic, and had no history of MI, stroke, or HF were included in this study. Our
147 process of harmonizing cohort data has been previously described.⁹⁻¹¹

148
149 **Outcomes:** Our outcome variables were first ASCVD, first MI (including fatal or
150 nonfatal), first stroke (including fatal or nonfatal), new onset HF, fatal MI, fatal stroke,
151 fatal ASCVD and all-cause mortality occurring within 10 years of baseline assessment.
152 These event types are biologically related, of high public health importance, and often
153 combined into single composite scores. All-cause mortality was included because of its
154 general importance. Since first ASCVD, first MI, and first stroke all included both fatal
155 and nonfatal events, there was substantial overlap between many of the outcome
156 variables. We used 10 years of follow-up because that is what was used in the PCEs,
157 the most important risk score in current ASCVD clinical practice.^{2,6}

158
159 **Predictors:** Predictor variables associated with the events under study in previous
160 research were chosen.^{6,12,13} They included age (years), gender (female vs male), race
161 or ethnicity (non-Hispanic Black, Hispanic, or non-Hispanic White), tobacco use
162 (current, former, or never), body-mass index (kg/m^2), low-density lipoprotein (LDL)
163 cholesterol (mg/dL), on cholesterol medications, history of diabetes, systolic BP
164 (mmHg), on BP medications, history of atrial fibrillation (no vs yes) and estimated
165 glomerular filtration rate ($\text{mL}/\text{min}/1.73\text{m}^2$). We also looked at interaction terms for
166 gender by age, gender by systolic BP, race/ethnicity by age, systolic BP by on BP
167 medications, LDL cholesterol by on cholesterol medications, and age-squared.
168 Interaction terms were selected based on previous research.^{6,12,13} Race and ethnicity
169 are included as imperfect markers of complex economic and sociocultural phenomena,
170 not as biological variables. Gender is included as a combination of both biological and
171 social variables.

172
173 **Analysis:** For our primary analyses we used logistic regression with elastic net
174 regularization (ENR) with alpha set at 0.75. ENR is like traditional regression models but
175 with added elements to reduce overfitting, which is where the model attributes to
176 prediction what is actually due to chance. In ENR this reduction is accomplished by
177 shrinking the observed predictions, either by assuming the true predictive effect of a
178 variable is smaller than that which is observed or by removing from the predictive model
179 variables that might improve prediction by a small amount, on the likelihood that the
180 benefit is only due to chance. The elastic net model does not show p-values for
181 individual predictor variables, but variables with effects smaller than a threshold based
182 on the selected alpha are removed from the model. The alpha is a way of choosing
183 which shrinkage technique to prioritize, with 0.75 reflecting our team's decision to

184 slightly prioritize removing variables from the model to yield a smaller, more
185 parsimonious model.

186
187 Unlike many existing models, we did not separate our models by race/ethnicity and
188 gender. We did this to minimize overfitting, because of existing research that this
189 approach is more effective and because we do not believe the biology of race, ethnicity,
190 or gender merits that separation.^{14,15}

191
192 To see how similar risk is between cardiovascular conditions, we compared predicted
193 risks from across all models using correlations. Then, to examine the clinical differences
194 between participants for whom our models gave a high predicted risk for different
195 conditions and the impact of treatment on their observed events, we identified
196 participants in the top quartile of risk for multiple measures and examined how they
197 differed from those in the top quartile for other event types. We used this to estimate the
198 likely clinical benefit of ASCVD reduction from one moderate dose BP medicine vs. one
199 moderate potency statin medicine for these groups of “isolated high risk.” BP
200 medications reduce stroke rates more than MI rates and statin medicines lower the
201 rates of each similarly.^{7,8} Therefore, people who are high stroke risk will have greater
202 benefit from BP medications than would be expected by ASCVD risk alone. We
203 hypothesized that we could identify people who are high stroke risk and that this would
204 differentially guide medication management to prevent more events with less
205 medication use. We used estimates of relative risk reduction from the Trialists
206 Treatment Collaboratives, estimating that a single moderate dose BP medicine lowers
207 systolic BP by 6.3 mmHg and a 5% reduction in BP lowers stroke rate by 19% and MI
208 rate by 6.3%. We estimated that a single moderate potency statin medicine lowers
209 stroke rate by 13% and MI rate by 14%.^{7,8}

210
211 One potentially important analytic concern was between-cohort heterogeneity. Different
212 cohorts can identify different event rates for participants with the same characteristics.
213 This limited external validity is most likely caused by an ascertainment bias, in which
214 some cohorts identified events that others may have missed, such as minor MIs. To
215 address this possibility, we developed a technique to normalize the results between
216 each cohort. First, we ran the models for each CVD outcome with a variable that
217 identifies the cohort. Next, we converted the beta-parameters for each cohort variable to
218 zero, so that differences that are attributable purely to cohort phenomenon were
219 removed. We then set a Y-intercept (beta-zero) to a value that yielded the same number
220 of predicted events as in the original model. The effect of this approach is to predict the
221 same number of events but remove the variability due to specific cohort effects.

222
223 **Evaluation:** All predictive models were first evaluated with visual inspection of the
224 predicted plots.¹⁶ We tested discrimination using the C-statistic (measuring the
225 likelihood that higher risk participants are more likely to have the outcome); calibration
226 using calibration slope, graphically (measuring how the predicted event rates match
227 observed rates without consistent over- or under-prediction); the ability to stratify
228 individual participant risk using interquartile range; and the calibration-in-the-large
229 (comparing the overall mean event rate with the overall predicted mean event rate). We

230 assessed overall accuracy using the Brier score (measuring overall accuracy of
231 prediction, in which larger errors are weighted more strongly) and internal validity. Our
232 primary internal validity check was a form of cross-validation in which we derived
233 models on 80% of the sample and then tested them on both the derivation sample and
234 the remaining 20% validation sample. We did this 10 times for each model to
235 understand the variability of the results. The validation results are the primary results.
236 The derivation samples were retained to observe how different it was from the validation
237 results. A larger change is a marker of overfitting.

238
239 **Sensitivity analyses:** We performed two sensitivity analyses. The first used logistic
240 regression without variable selection instead of regression penalized with ENR. In
241 theory ENR will minimize overfitting, which will make it more effective when the sample
242 size is small relative to the number of predictor variables. ENR is, however, less easily
243 available and takes much longer computational time. The second sensitivity analysis
244 looked at using 5-year risk scores instead of 10. Ten-year scores are more common in
245 ASCVD research and practice, but having enough follow-up is not always practical and
246 it's possible that 10 years of follow-up doesn't reflect that person's immediate needs as
247 well as 5 years.

248
249

250 Results

251

252 Our sample's mean age was 58.6 and was 55.6% women. The mean BP was 138.4. Of
253 all participants, 20.7% were non-Hispanic Black and 10.2% were Hispanic (Table 1).
254 Almost half the people in the study (47.4%) were from the ARIC cohort.

255

256 Our primary models for all 10-year risk predictions are presented in Table 2. White race
257 was not independently associated with MI, HF, or fatal MI, but was negatively
258 associated with stroke, ASCVD, all-cause mortality, fatal ASCVD, and fatal stroke,
259 compared to non-Black Hispanic ethnicity. Black race was associated with increased
260 stroke and MI rates. Both higher systolic BP and being on BP lowering medicine were
261 associated with increased risk of every outcome. We did identify interaction effects
262 between race/ethnicity and other risk factors. In particular, the impact of BP was greater
263 in Black participants for almost all outcomes, as indicated by positive Black-by-SBP
264 interactions.

265

266 We did identify cohort-specific effects, including that participants in CHS may have had
267 increased sensitivity to mild events as participants were more likely to have events than
268 their risk factor profile would otherwise predict, but were less likely to die. Participants
269 from the FHS had more fatal and nonfatal events than their risk factor profiles would
270 otherwise predict, ARIC had fewer diagnoses of HF than would have been predicted
271 from other studies. Table 2 contains the entire model results including the constant. By
272 applying these results in a logistic regression formula these results could be used and
273 replicated.

274

275 Our models' assessments showed good predictive capacity by visual inspection of
276 predicted probabilities (Supplemental Figures 1-8). C-statistics were between 0.745 (for
277 MI) and 0.85 (for HF) (Table 3). Our models were well calibrated as evidenced by the
278 excellent values for Brier Score, calibration-in-the-large, and visual assessment (Table 3
279 and supplementary figures 1-8). The small differences between the c-statistics of the
280 derivation and validation shows limited overfitting, also verified by the relatively small
281 between-run standard deviation of that difference, which was never greater than 0.04.
282 The models show good separation, with 25th-75th percentile results differentiating
283 effectively for this low-risk pooled cohort. For every outcome, the bottom 25th percentile
284 threshold was below a 4% risk of an event in 10 years and the 75th percentile of risk
285 was at least three times higher. For overall ASCVD events, people at the 25th percentile
286 had a 2.7% 10-year predicted event rate and those in the 75th percentile had an 8.3%
287 rate. The observed-to-expected figures of all models are included in the supplemental
288 appendix (Supplemental Figures 1-8). They consistently show excellent calibration for
289 well over 90 percent of participants in all models, with substantial error occurring only in
290 the very high-risk tails.

291
292 Individual participants' predicted risks for different outcomes were strongly correlated
293 with one another, but the magnitude of correlation varied across different comparisons
294 (Table 4). The correlation coefficient between 10-year risk of MI and stroke, as well as
295 that between MI and all-cause mortality, was 0.68 ($R^2 = 46\%$). The correlation between
296 risk of all MI and risk of fatal MI was 0.85 ($R^2 = 72\%$). Stroke and HF were more closely
297 correlated with all outcomes (all-cause mortality, fatal ASCVD, and fatal stroke) than MI.
298 The only exception is that MI was more closely associated with fatal MI than HF. The
299 strongest correlation was between fatal MI and fatal ASCVD, with a correlation
300 coefficient of 0.97. Fatal MI is the largest component of fatal ASCVD.

301
302 Next, we wanted to determine if participants at high risk for one outcome were
303 meaningfully different from those at high risk for others. To do this, we identified
304 participants who were in the top quartile for risk of MI, stroke, and all-cause mortality. In
305 Table 5, we describe all participants who were in the top quartile for one of those three
306 outcomes, but not the other two. Participants who were particularly high risk for MI but
307 not stroke were disproportionately White, had higher LDL cholesterol levels and higher
308 rates of tobacco use, and had lower rates of diabetes than those at high risk for stroke
309 and all-cause mortality. Participants with top-quartile risk of stroke but not MI or
310 mortality were disproportionately female and obese, had higher systolic BP levels, and
311 were more likely to have diabetes. Participants with top-quartile risk of all-cause
312 mortality but not of MI or stroke were strikingly older than the other high-risk groups, had
313 lower values on all traditional ASCVD risk factors, including BP, BMI, LDL, and
314 proportion with diabetes. Their rates of tobacco use were higher than those with high
315 risk of stroke but lower than those with high risk of MI.

316
317 We also found a difference in absolute risk reduction in events between participants
318 who are top-quartile in risk of MI but not stroke or mortality vs. those who are top-
319 quartile in risk of stroke but not MI or mortality when treated with a BP-lowering
320 medications vs cholesterol lowering (Table 5). In participants who had top quartile of

321 risk of MI, but not of stroke or all-cause mortality, one BP-lowering medication for 10
322 years would have an estimated 2.4% chance of preventing a first ASCVD event. A
323 moderate-strength statin would have a 2.1% chance of preventing an event in the same
324 period. In distinction, in participants who had top quartile risk of stroke but not MI or
325 mortality, a BP medication would have a similar chance (2.5%) of preventing an event,
326 but a moderate-strength statin would have a reduced chance (1.6%) chance of
327 preventing an event. Participants with top-quartile risk of mortality but not MI or stroke
328 had a smaller benefit for both treatments, with a 1.3% reduction in ASCVD with a
329 moderate-strength statin and a 1.8% reduction from a BP medication.

330
331 Figure 1 also demonstrates this phenomenon. In an intermediate-risk group of 10-year
332 ASCVD risk from 7.5% to 15%, the more a participant's risk was due to stroke risk, the
333 greater the benefit of BP-lowering medication. The more their risk was due to MI risk,
334 the greater the benefit of a statin (Figure 1). Each dot represents one cohort participant.

335
336 We performed two prespecified sensitivity analyses. One assessed the impact of using
337 logistic regression without variable selection instead of our primary modeling technique
338 of penalized regression and selection using ENR (Supplemental Tables S2-S5). We
339 found that ENR had substantial benefits in quality of risk prediction, with validation c-
340 statistics more than 0.05 better in the models predicting stroke, CHF, fatal ASCVD, and
341 fatal stroke using ENR than logistic regression without variable selection. The
342 correlations between the predictions were virtually unchanged, with only one
343 comparison more than 0.05 different from the results in the primary ENR models.

344
345 The second sensitivity analysis tested the impact of using 5-year risk scores instead of
346 10 years (Supplemental Tables S6-S9). The effects of this were small, with validation C-
347 statistics less than 0.02 different between 5-year and 10-year models in 6 of 8 models.
348 We have included all models in the supplement.

349 350 **Discussion**

351 In this study we developed risk equations for eight cardiovascular events using pooled
352 data from five large, US cardiovascular cohort studies, first atherosclerotic
353 cardiovascular disease (ASCVD), first fatal or nonfatal MI, first fatal or nonfatal stroke,
354 new-onset HF, fatal ASCVD, fatal MI, fatal stroke, and all-cause mortality. We found
355 that correlations between the risk of different types of cardiovascular disease, such as
356 MI and stroke, were strong, usually between 0.7 and 0.88. Despite these correlations,
357 we could identify high-risk participants who were 2.5 times as likely to have a stroke
358 than an MI and others who were 2.5 times as likely to have an MI than a stroke. We
359 then found that this would impact the likely benefit of taking a statin vs. a BP-lowering
360 medication.

361
362 The risk scores we developed have advantages over previous cardiovascular risk
363 scores. First, we developed it using multiple cohorts that had rigorous attention paid to
364 data accuracy and case ascertainment. Our cohorts are closely related to the Pooled
365 Cohort Equation cohorts, which allows comparison with the most common risk score
366 used today. While risk equations exist for multiple outcomes, relatively few have allowed

367 comparability by using the same method for each outcome.^{17,18} We used modern
368 techniques, including ENR, testing for overfitting with cross-validation, and assessing
369 using modern methods such as the Brier score. Our cohorts were developed from
370 geographically and racially diverse populations of US adults, included Hispanic adults,
371 and included variables, such as statin treatment, that are not included in the PCEs. We
372 evaluated the potential impact of the scores and found meaningful differences in
373 treatment benefit among people with the same ASCVD risk.

374
375 We found that participants who were particularly high risk for one cardiovascular
376 outcome were not necessarily high-risk in the others. Participants with high risk of MI
377 were disproportionately White males with high LDL cholesterol levels and rates of
378 tobacco use. Those with high risk of stroke were more likely to be Black women with
379 high BP and BMI. This finding is consistent with studies showing greater risk of stroke in
380 Black women than White women, a disparity that is highest at ages 50 to <60 years old,
381 but persists after age 70.¹⁹ Unsurprisingly, those with a high risk of all-cause mortality
382 were strikingly older than other high risk groups.

383
384 Finally, we found that by identifying patients who are high risk of stroke, but not MI or
385 all-cause mortality, we could isolate patients with a greater likely benefit of BP-lowering.
386 The greater proportion of an individual's risk that was due to MI, the greater the benefit
387 of statin. Participants with a risk of MI in the top quartile but not stroke or all-cause
388 mortality had a 15% greater benefit in total ASCVD outcome from a single BP-lowering
389 medication (2.4% vs. 2.1% 10-year reduction). But in those with a top-quartile risk of
390 stroke but not heart disease or all-cause mortality, the risk reduction for total ASCVD
391 was 56% greater (2.5% vs. 1.6% 10-year reduction). Participants with elevated all-
392 cause mortality had substantially lower probability of benefitting from either drug (1.8%
393 10-year reduction for one BP-lowering medication and 1.3% from a statin). While not
394 ready for clinical practice, these results shows that we could imagine personalizing care
395 to maximize benefit based on a person's elevated risk for a specific clinical outcome.
396 For example, we may be more likely to consider BP reduction use in people at higher
397 risk of stroke, due to those drug's greater differential effectiveness in those conditions.
398 Similarly, the glucose-lowering drugs sodium-glucose cotransporter 2 inhibitors appear
399 to be effective at MI prevention but do not seem to reduce rates of strokes; some
400 evidence implies the glucagon-like peptide-1 receptor -1 analogs reduce strokes more
401 effectively than reduce MIs.²⁰

402
403 In our study, each cohort had slightly different findings, particularly in overall event
404 rates. This phenomenon, which has been seen before,^{15,21} demonstrates a larger concern
405 for external validity in all predictive model research.^{15,21} We addressed this by removing
406 the cohort effect and normalizing the Y-intercept. This minimizes multiple biases but
407 there is no way to be certain that between-cohort differences could have created effects
408 seen only in specific variables. The data in this study were obtained at different times in
409 many locations across the United States. From the time of data acquisition, many care
410 practices have changed, most dramatically an increased rate of statin use and
411 continued decline in tobacco use. Almost half of our data is from the ARIC cohort.

412

413 Another limitation is the non-causal nature of risk scores and the subjectivity in
414 developing them. Higher risk participants will not necessarily receive more benefit from
415 treatment, though existing research indicates they usually do.^{23–25} Our results would
416 have changed slightly with different analytic choices, including the unavoidably
417 subjective nature of which potential predictor variables to include. We opted to use
418 variables that have been used many times in cardiovascular prediction and are easy to
419 obtain clinically. Some potential predictors, such as use of newer diabetes medicines,
420 were not included because data from the cohorts was not recent enough.

421
422 Our work shows that it is valuable to predict cardiovascular outcomes independently,
423 while also providing the tools to do so. These results have many possible utilities. They
424 could be used clinically by participants who are particularly concerned about one event
425 type over another. They could be used in cost effectiveness studies and policy
426 simulations to guide the accuracy of using treatments that are more effective at
427 preventing one event type vs. another. They could also help guide population health
428 interventions. Future work should include understanding how much integrating these
429 findings into clinical and public health practice can influence outcomes.

430
431

432 **Acknowledgements**

433
434 This research project is supported by a grant R01 NS102715 from the National Institute
435 of Neurological Disorders and Stroke (NINDS), National Institutes of Health, Department
436 of Health and Human Service. The NINDS was not involved in the design and conduct
437 of the study; collection, management, analysis, and interpretation of the data;
438 preparation, review, or approval of the manuscript; and decision to submit the
439 manuscript for publication except one representative (author RFG) of the funding
440 agency reviewed the manuscript. The content is solely the responsibility of the authors
441 and does not necessarily represent the official views of the National Institute of
442 Neurological Disorders and Stroke or the National Institutes of Health.

443
444 This research was supported by contracts HHSN268201200036C,
445 HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079,
446 N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086,
447 75N92021D00006, and grants U01HL080295 and U01HL130114 from the National
448 Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National
449 Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided
450 by R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS
451 investigators and institutions can be found at [CHS-NHLBI.org](https://chs-nhlbi.org). The content of this
452 manuscript is solely the responsibility of the authors and does not necessarily represent
453 the official views of the National Institutes of Health

454
455 The Framingham Heart Study (FHS) is conducted and supported by the National Heart,
456 Lung, and Blood Institute (NHLBI) in collaboration with Boston University (Contract No.
457 N01-HC-25195, HHSN2682015000011 and 75N92019D00031). This manuscript was
458 not prepared in collaboration with investigators of the Framingham Heart Study and
459 does not necessarily reflect the opinions or views of the Framingham Heart Study,
460 Boston University, or NHLBI.

461
462 The Multi-Ethnic Study of Atherosclerosis study (MESA) is conducted and supported by
463 the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA
464 investigators. Support for MESA is provided by contracts N01-HC95159, N01-HC-
465 95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-
466 95165, N01-HC95166, N01-HC-95167, N01-HC-95168, N01-HC-95169 and CTSA UL1-
467 RR-024156.

468
469 The Atherosclerosis Risk in Communities study has been funded in whole or in part with
470 Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of
471 Health, Department of Health and Human Services, under Contract nos.
472 (75N92022D00001, 75N92022D00002, 75N92022D00003, 75N92022D00004,
473 75N92022D00005). Additionally, Dr. Gottesman was supported by the NINDS
474 intramural research program. The authors thank the staff and participants of the ARIC
475 study for their important contributions.

476

477 The Northern Manhattan Stroke (NOMAS) study has been funded at least in part with
478 federal funds from the National Institutes of Health, National Institute of Neurological
479 Disorders and Stroke by R01 NS29993, AG066162 and AG057709.

480

481

482

483

484

485

486

487

488

| Table 1: Baseline characteristics | |
|--|------------------------------------|
| Characteristics | Participants (n=24,505) |
| Age, mean (SD), y | 58.6 (9.7) |
| Women, n,% | 13,627 (55.6) |
| Tobacco use, n,% | 5,308 (21.7) |
| Systolic Blood Pressure, mean (SD), mmHg | 138.4 (20.6) |
| BMI, mean (SD), kg/m ² | 27.7 (5.2) |
| LDL cholesterol, mean, (SD), mg/dL | 131.5 (37.4) |
| Diabetes, n,% | 2,415 (10.0) |
| eGFR, mean (SD), mL/min | 74.9 (17.2) |
| Race/Ethnicity | |
| Non-Hispanic Black, n,% | 5,084 (20.7) |
| Non-Hispanic White, n,% | 16,924 (69.1) |
| Hispanic, n,% | 2,497 (10.2) |
| Study | |
| ARIC, n, % | 11,625 (47.4) |
| CHS, n, % | 3,755 (15.3) |
| FOS, n, % | 1,801 (7.4) |
| MESA, n, % | 5,613 (23.0) |
| NOMAS, n, % | 1,709 (7.0) |

489

490

Table 2: Beta-coefficients for all 10-year outcomes

| | ASCVD | MI | Stroke | HF | All-Cause Mortality | Fatal ASCVD | Fatal MI | Fatal Stroke |
|-----------------------------------|----------------|--------------|---------------|--------------|----------------------------|--------------------|-----------------|---------------------|
| | (1,696 events) | (927 events) | (865 events) | (885 events) | (2,843 events) | (446 events) | (301 events) | (145 events) |
| Female | -0.49 | | -0.475 | | 0.46 | -0.242 | | -0.475 |
| White | -0.33 | | -1.223 | | -0.93 | -0.22 | | -1.22 |
| Black | 0.36 | | 1.374 | | | | | 1.37 |
| Current smoker | 0.70 | 0.742 | 0.51 | 0.632 | -0.0037 | -0.00525 | 0.0024 | |
| BMI | 0.0024 | 0.004 | | 0.0393 | -0.00048 | 0.00558 | 0.0072 | 0.001 |
| LDL | 0.0058 | 0.0083 | 0.001 | | -0.223 | | | 0.097 |
| Cholesterol tx | -0.00617 | | 0.097 | | 0.778 | 0.818 | 0.862 | 0.63 |
| Diabetes | 0.689 | 0.6910 | 0.631 | 0.708 | 0.0055 | 0.0176 | 0.0142 | 0.012 |
| SBP | 0.0117 | 0.0095 | 0.012 | 0.0109 | 0.409 | 0.715 | 0.521 | 1.82 |
| BP tx | 1.384 | 0.87 | 1.819 | 0.386 | 0.734 | 0.526 | 0.224 | 0.34 |
| Atrial fibrillation | 0.35 | 0.291 | 0.344 | 1.287 | -0.0059 | -0.0086 | -0.0094 | -0.001 |
| eGFR | -0.0027 | -0.0046 | -0.0012 | -0.0095 | 0.0185 | 0.00402 | 0.0102 | -0.0002 |
| Age X Age | 0.00038 | | 0.0004 | 0.00051 | 0.0015 | | | |
| Black X Age | -0.0168 | -0.0083 | -0.027 | | 0.0006 | 0.000488 | 0.000032 | 0.0004 |
| Hispanic X Age | 0.00023 | 0.013 | | | 0.0183 | | | 0.0129 |
| Age | | 0.0247 | | | -0.0033 | | | -0.027 |
| Black X SBP | 0.00244 | 0.00073 | 0.0027 | 0.0000307 | | 0.00312 | 0.0487 | |
| Hispanic X SBP | -0.00172 | -0.0063 | -0.0005 | | -0.00107 | | | |
| LDL X Off Cholesterol Treatment | 0.00010 | | 0.0015 | | 0.00474 | 0.00117 | 0.00228 | 0.0027 |
| SBP X On Blood Pressure Treatment | 0.00663 | 0.0035 | 0.0092 | | -0.000229 | | | 0.0015 |
| Male X Age | | 0.0116 | 0.00024 | 0.00475 | 0.00173 | 0.00133 | | 0.0092 |
| LDL X On Cholesterol Treatment | | 0.000558 | | -0.00106 | | 0.000576 | 0.00175 | |
| Female X Age | | | 0.00914 | | | | | 1.37 |
| Male X SBP | | | 0.00206 | | | | | 0.009 |
| White X Age | | | 0.0129 | | | | | 0.002 |
| White X SBP | | | | 0.000709 | | | | 0.000 |

| | | | | | | | | |
|--------------|---------|--------|-------|--------|---------|--------|--------|-------|
| CHS | 0.76 | 0.71 | 0.91 | 3.151 | -0.136 | -0.593 | -0.88 | 0.91 |
| FHS | 0.80 | 0.79 | 0.69 | 1.997 | 0.351 | 0.901 | 0.866 | 0.69 |
| MESA | -0.0438 | -0.275 | 0.17 | 2.114 | -0.413 | -0.291 | -0.232 | 0.17 |
| NOMAS | 0.244 | -0.306 | 0.64 | 2.75 | -0.0647 | -0.762 | -1.066 | 0.64 |
| Constant | -7.469 | -8.39 | -8.96 | -10.27 | -6.197 | -9.037 | -10.61 | -8.96 |
| Observations | 24505 | 24505 | 24505 | 24505 | 24505 | 24505 | 24505 | 24505 |

Legend: Non-predictive variables are naturally removed in this modeling technique.

Abbreviations: ASCVD atherosclerotic cardiovascular disease, BMI body mass index, BP blood pressure, BP tx blood pressure treatment, CHS Cardiovascular Health Study, eGFR estimated glomerular filtration rate, Framingham Offspring Study (FOS), LDL low density lipoprotein, MESA Multi-Ethnic Study of Atherosclerosis, MI myocardial infarction, NOMAS Northern Manhattan Study, SBP systolic blood pressure

Table 3: Validation statistic for every 10-year model. Each model was run 10 times on random 80% derivation samples then assessed on the remaining 20%.

| Outcome | ASCVD | MI | Stroke | HF | All-Cause Mortality | Fatal ASCVD | Fatal MI | Fatal Stroke |
|--|--------|--------|--------|-------|---------------------|-------------|----------|--------------|
| C-statistic: Derivation | 0.753 | 0.745 | 0.794 | 0.852 | 0.776 | 0.836 | 0.748 | 0.813 |
| C-statistic: Validation | 0.758 | 0.750 | 0.802 | 0.850 | 0.775 | 0.834 | 0.752 | 0.827 |
| C-statistic: Derivation-Validation Difference | -0.005 | -0.004 | -0.007 | 0.002 | 0.001 | 0.002 | -0.004 | -0.013 |
| C-statistic: Std Dev of Derivation-Validation Difference | 0.061 | 0.036 | 0.033 | 0.034 | 0.089 | 0.038 | 0.012 | 0.006 |
| Brier Score: Derivation | 0.059 | 0.034 | 0.032 | 0.034 | 0.089 | 0.037 | 0.012 | 0.005 |
| Brier Score: Validation | 0.000 | 0.000 | 0.000 | 0.001 | 0.000 | 0.000 | 0.000 | 0.000 |
| Brier Score: Derivation-Validation Difference | 0.059 | 0.034 | 0.032 | 0.033 | 0.089 | 0.037 | 0.012 | 0.005 |
| Calibration in the large: Derivation | 0.000 | 0.000 | 0.000 | 0.001 | 0.000 | 0.000 | 0.000 | 0.000 |
| Calibration in the large: validation | 0.000 | 0.000 | 0.000 | 0.001 | 0.000 | 0.000 | 0.000 | 0.000 |
| Risk: 25th percentile | 0.027 | 0.015 | 0.009 | 0.004 | 0.035 | 0.008 | 0.004 | 0.001 |
| Risk: 50th percentile | 0.047 | 0.026 | 0.019 | 0.007 | 0.073 | 0.014 | 0.008 | 0.003 |
| Risk: 75th percentile | 0.083 | 0.043 | 0.040 | 0.015 | 0.159 | 0.027 | 0.016 | 0.007 |


Table 4: Correlations between risk of 10-year outcomes

| | ASCVD | MI | Stroke | HF | All-Cause Mortality | Fatal ASCVD | Fatal MI | Fatal Stroke |
|---------------------|-------|------|--------|------|---------------------|-------------|----------|--------------|
| ASCVD | 1 | | | | | | | |
| MI | 0.91 | 1 | | | | | | |
| Stroke | 0.92 | 0.68 | 1 | | | | | |
| HF | 0.83 | 0.70 | 0.83 | 1 | | | | |
| All-Cause Mortality | 0.83 | 0.68 | 0.82 | 0.86 | 1 | | | |
| Fatal ASCVD | 0.92 | 0.79 | 0.91 | 0.87 | 0.83 | 1 | | |
| Fatal MI | 0.92 | 0.85 | 0.85 | 0.81 | 0.79 | 0.97 | 1 | |
| Fatal Stroke | 0.79 | 0.58 | 0.88 | 0.80 | 0.74 | 0.91 | 0.80 | 1 |

Table 5: Descriptive characteristics of different high-risk groups

| | MI risk top quartile, not stroke or mortality (N=1,840)* | Stroke risk top quartile, not MI or mortality not (N=1039) | All-cause mortality risk top quartile, not stroke or MI not (N=887) |
|---|--|--|---|
| Age, mean (SD), y | 56.5 (5.8) | 59.9 (8.1) | 70.3 (5.4) |
| Women, n, % | 373 (20) | 790 (76) | 364 (41) |
| Race/Ethnicity | | | |
| Black, n, % | 13 (1) | 655 (63) | 238 (27) |
| White, n, % | 1454 (95) | 158 (24) | 611 (69) |
| Hispanic, n, % | 83 (5) | 227 (22) | 38 (4) |
| Systolic BP, mean (SD), mmHg | 143 (16.4) | 156 (18.0) | 128 (14.0) |
| Tobacco use, n, % | 841 (46) | 125 (12) | 26 |
| BMI, mean (SD), kg/m ² | 28.0 (4.5) | 30.6 (6.3) | 25.7(4.4) |
| LDL cholesterol, mean (SD), mg/dL | 169 (39.1) | 131.2 (34.5) | 108.8 (29.5) |
| Diabetes, n, % | 169 (9) | 186 (18) | 44 (5) |
| GFR, mean (SD), mL/min/1.73m ² | 69.1 (13.0) | 81.3 (17.1) | 74.7 (16.3) |
| 10-year predicted MI rate, % | 6.6 | 3.2 | 3.2 |
| 10-year predicted stroke rate, % | 2.7 | 5.9 | 3.3 |
| Estimated absolute 10-year ASCVD reduction from a statin, % | 2.1 | 1.6 | 1.3 |
| Estimated absolute 10-year ASCVD reduction from a BP-lowering medicine, % | 2.4 | 2.5 | 1.8 |
| Abbreviations: ASCVD atherosclerotic cardiovascular disease, BMI body mass index, BP blood pressure, GFR glomerular filtration rate, LDL low density lipoprotein, MI myocardial infarction, SD standard deviation | | | |

Figure 1: Absolute risk reduction due to one blood pressure lowering medicine vs. a moderate-strength statin in every study participant with 7.5%-15% 10-year risk by probability that their event would be a stroke. Each dot is a study participant, the lines represent the linear regression of the relationship between percentage of events that are predicted to be strokes and the absolute risk reduction of any ASCVD event in 10 years.



References

1. Whelton PK, Williams B. The 2018 European Society of Cardiology/European Society of Hypertension and 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines: More Similar Than Different. *JAMA*. 2018;320(17):1749-1750. doi:10.1001/jama.2018.16755
2. Arnett DK, Khera A, Blumenthal RS. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Part 1, Lifestyle and Behavioral Factors. *JAMA Cardiol*. 2019;4(10):1043-1044. doi:10.1001/jamacardio.2019.2604
3. O'Malley PG, Arnold MJ, Kelley C, et al. Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. *Ann Intern Med*. 2020;173(10):822-829. doi:10.7326/M20-4648
4. Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. 2016;316(19):2008-2024. doi:10.1001/jama.2015.15629
5. US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2022;327(16):1577-1584. doi:10.1001/jama.2022.4983
6. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2018;138(17):e484-e594. doi:10.1161/CIR.0000000000000596
7. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. *Lancet Lond Engl*. 2021;397(10285):1625-1636. doi:10.1016/S0140-6736(21)00590-0
8. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet Lond Engl*. 2016;388(10059):2532-2561. doi:10.1016/S0140-6736(16)31357-5
9. Levine DA, Gross AL, Briceño EM, et al. Sex Differences in Cognitive Decline Among US Adults. *JAMA Netw Open*. 2021;4(2):e210169. doi:10.1001/jamanetworkopen.2021.0169
10. Levine DA, Gross AL, Briceño EM, et al. Association Between Blood Pressure and Later-Life Cognition Among Black and White Individuals. *JAMA Neurol*. 2020;77(7):810-819. doi:10.1001/jamaneurol.2020.0568
11. Levine DA, Gross AL, Briceño EM, et al. Blood Pressure and Later-Life Cognition in Hispanic and White Adults (BP-COG): A Pooled Cohort Analysis of ARIC, CARDIA, CHS, FOS, MESA, and NOMAS. *J Alzheimers Dis JAD*. 2022;89(3):1103-1117. doi:10.3233/JAD-220366
12. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. 2008;117(6):743-753. doi:10.1161/CIRCULATIONAHA.107.699579
13. Sussman JB, Wiitala WL, Zawistowski M, Hofer TP, Bentley D, Hayward RA. The Veterans Affairs Cardiac Risk Score: Recalibrating the Atherosclerotic Cardiovascular Disease Score for Applied Use. *Med Care*. 2017;55(9):864-870. doi:10.1097/MLR.0000000000000781

14. Borrell LN, Elhawary JR, Fuentes-Afflick E, et al. Race and Genetic Ancestry in Medicine - A Time for Reckoning with Racism. *N Engl J Med*. 2021;384(5):474-480. doi:10.1056/NEJMms2029562
15. Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min YI, Basu S. Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk. *Ann Intern Med*. 2018;169(1):20-29. doi:10.7326/M17-3011
16. Royston P, Altman DG. Visualizing and assessing discrimination in the logistic regression model. *Stat Med*. 2010;29(24):2508-2520. doi:10.1002/sim.3994
17. Basu S, Sussman JB, Berkowitz SA, Hayward RA, Yudkin JS. Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODE) using individual participant data from randomised trials. *Lancet Diabetes Endocrinol*. 2017;5(10):788-798. doi:10.1016/S2213-8587(17)30221-8
18. Basu S, Sussman JB, Berkowitz SA, et al. Validation of Risk Equations for Complications of Type 2 Diabetes (RECODE) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S. *Diabetes Care*. 2018;41(3):586-595. doi:10.2337/dc17-2002
19. Jiménez MC, Manson JE, Cook NR, et al. Racial Variation in Stroke Risk Among Women by Stroke Risk Factors. *Stroke*. 2019;50(4):797-804. doi:10.1161/STROKEAHA.117.017759
20. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. *BMJ*. Published online January 13, 2021:m4573. doi:10.1136/bmj.m4573
21. Wessler BS, Nelson J, Park JG, et al. External Validations of Cardiovascular Clinical Prediction Models: A Large-Scale Review of the Literature. *Circ Cardiovasc Qual Outcomes*. 2021;14(8):e007858. doi:10.1161/CIRCOUTCOMES.121.007858
22. Tsao CW, Aday AW, Almarazooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation*. 2022;145(8):e153-e639. doi:10.1161/CIR.0000000000001052
23. Kent DM, Paulus JK, van Klaveren D, et al. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. *Ann Intern Med*. 2020;172(1):35-45. doi:10.7326/M18-3667
24. Kent DM, Nelson J, Dahabreh IJ, Rothwell PM, Altman DG, Hayward RA. Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. *Int J Epidemiol*. 2016;45(6):2075-2088. doi:10.1093/ije/dyw118
25. Sussman JB, Kent DM, Nelson JP, Hayward RA. Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. *BMJ*. 2015;350:h454. doi:10.1136/bmj.h454